New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes
Type 2 diabetes mellitus (T2DM) is closely associated with the risk of developing cardiovascular complications. A new approach to treatment of T2DM, based on the inhibition of the sodium-glucose cotransporter type 2 (SGLT2) ensures reliable insulin-independent glycemic control with quick overcome of...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Russo |
| Vydáno: |
Remedium Group LLC
2020-05-01
|
| Edice: | Медицинский совет |
| Témata: | |
| On-line přístup: | https://www.med-sovet.pro/jour/article/view/5653 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|